RS BioTherapeutics (Convertible Notes)

Funding Details
Awarder
StartEngine
Date Award
April 24, 2024
Vertical
Biopharmaceuticals
Funding URL
View Funding Page
Premoney Valuation
$40,000,000
Valuation
$40,000,000

Company Info
Founding Year
Not provided
Traction
None
Organizations Involved
None
Founders
Dean Hart, Michelle L. Shuffett, Curtis Rhine, Justin Molignoni
Company Description
RS BioTherapeutics is developing a groundbreaking drug platform to address inflammatory lung diseases like Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). Their science-backed approach offers new treatment avenues not just for these respiratory diseases, but many others that could be addressed using their innovative platform.
Market
Respiratory Diseases
Location
Cumberland, MD, US
Coinvestors
None

Links
Back to Home Back to Biopharmaceuticals Deals View Funding Announcement